Endologix Reports First Quarter 2020 Financial Results

Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced its financial results for the first quarter ended March 31, 2020. The Company’s financial results are preliminary and subject to any adjustments that may occur following the completion of the quarterly review of the Company’s financial statements by its independent auditor.

Global revenue in the first quarter of 2020 was $28.51 million, a 19.9% decrease from $35.61 million in the first quarter of 2019.

“Our first quarter results were impacted by the deferral of AAA procedures related to the COVID-19 pandemic,” commented John Onopchenko, Chief Executive Officer of Endologix, Inc. “We are confident that these deferred procedures will be rescheduled once hospitals widen the criteria for treating AAA patients from today's 'emergent only' standard. As we navigate this pandemic, our top priority remains the safety of our employees as well as the patients, surgeons, and affiliated caregivers that we serve. As hospitals resume a more normalized level of care, we are also focused on ensuring the continued availability of products to patients in need. We are taking the necessary actions to prepare for a return to pre-pandemic procedure volume and to provide necessary case support and ongoing execution of our continuous improvement mandate.”

Financial Results

U.S. revenue in the first quarter of 2020 was $18.6 million, a 18.2% decrease from $22.8 million in the first quarter of 2019.

International revenue in the first quarter of 2020 was $9.9 million, a 22.9% decrease from $12.8 million in the first quarter of 2019. On a constant currency basis, international revenue decreased 21.1% compared to the first quarter of 2019.

Gross profit was $15.1 million in the first quarter of 2020, representing a gross margin of 53.1%. This compares to a gross profit of $23.2 million, or a gross margin of 65.2%, in the first quarter of 2019. Gross profit in the first quarter of 2020 was negatively impacted by unfavorable variances associated with lower revenue.

Total operating expenses in the first quarter of 2020 were $31.3 million, a 11.0% decrease from $35.2 million in the first quarter of 2019. Operating expenses in the first quarter of 2019 included $0.4 million of costs associated with restructuring. Excluding these items, operating expenses decreased 9.9% compared to the first quarter of 2019.

Net Loss for the first quarter of 2020 was $18.1 million, or $(0.90) per share, compared to a Net Loss of $22.0 million, or $(2.12) per share, a year ago. Adjusted Net Loss (non-GAAP measure, defined below) totaled $16.2 million, compared to an Adjusted Net Loss of $11.7 million for the first quarter of 2019. Adjusted EBITDA loss (non-GAAP measure, defined below) totaled $13.2 million for the first quarter of 2020, compared to Adjusted EBITDA loss of $7.6 million a year ago.

Total cash, cash equivalents, and restricted cash were $42.2 million as of March 31, 2020, compared to $42.8 million as of December 31, 2019. The March 31, 2020 balance included $10.5 million outstanding under the Company's revolving credit facility with certain affiliates of Deerfield Management Company, L.P.

Fiscal Year 2020 Financial Guidance

The Company believes that COVID-19 pandemic will continue to have a negative impact on its financial results and business operations. Due to the uncertainty surrounding the magnitude of COVID-19’s spread and evolution, as well as the present inability to accurately forecast the ultimate impact to the Company’s operations and financial results, management has withdrawn the Company’s previously issued financial guidance for 2020 and will not be providing financial guidance at this time.

Conference Call Information

The Company's management will host a conference call today at 4:30 p.m. ET (1:30 p.m. PT) to discuss its first quarter 2020 results.

To participate in the conference call, dial 800-263-0877 (domestic) or [phone] (international) and refer to the passcode 4426442.

This conference call will also be webcast and can be accessed from the “Investors” section of the Company’s website at www.endologix.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available from 7:30 p.m. ET on Monday, May 11, 2020, until 11:59 p.m. ET on Monday, May 18, 2020. To hear this recording, dial 844-512-2921 (domestic) or [phone] (international) and enter the passcode 4426442.

About Endologix, Inc.

The Company develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is in endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once an AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. For more information, visit www.endologix.com.

The Nellix® EndoVascular Aneurysm Sealing System has a CE Mark and is an investigational device in the United States. The Ovation Alto® System has obtained FDA approval in the United States and is presently an investigational device in the EU.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can generally be identified by the use of words such as “anticipate,” “expect,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the impact of COVID-19 on the Company’s operations and financial results, the rescheduling of deferred procedures, the normalizing of healthcare services, the Company’s preparedness for a return to pre-pandemic procedure volume and related case support, the Company’s ability to maintain compliance with its covenants under its debt arrangements, and the Company’s confidence that continued execution and commitment to its culture of accountability will enable it to achieve, profitable, long-term growth; accuracy of which are necessarily subject to risks and uncertainties that may cause the Company’s actual results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ materially and adversely from anticipated results include the scope and duration of the COVID-19 pandemic, the cancellation of deferred procedures, continued market acceptance, endorsement and use of the Company’s products, the Company’s continued compliance with its financial covenants and other operating restrictions under its lending facilities, the Company’s ability to access the capital markets on terms acceptable to it or at all, the Company’s abilities to service its indebtedness and to satisfy and discharge its indebtedness as such indebtedness comes due, the success of clinical trials relating to the Company’s products, product research and development efforts, uncertainty in the process of obtaining and maintaining regulatory approval for the Company’s products, the Company's ability to protect its intellectual property rights and proprietary technologies, the Company’s ability to retain its key executive, sales and other personnel, and other economic, business, competitive, and regulatory factors. Forward-looking statements represent management’s current expectations and predictions about trends affecting the Company's business and industry and are based on information available as of the time such statements are made. The forward-looking statements contained in this press release speak only as of the date of this press release. The Company undertakes no obligation to update any forward- looking statements contained in this press release to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent Quarterly Reports on Form 10-Q for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied in the forward-looking statements.

Discussion of Non-GAAP Financial Measures

The Company’s management believes that the non-GAAP measures of (1) “Adjusted Net Income (Loss)” and (2) “Adjusted EBITDA” enhance an investor’s overall understanding of the Company’s financial and operating performance and its future prospects by (i) being more reflective of core operating performance and (ii) being more comparable with financial results over various periods. These measures, when used in conjunction with related financial measures calculated in accordance with generally accepted accounting principles in the United States (“GAAP”), provide investors with an additional financial analytical framework that may be useful in assessing the Company’s financial condition and results of operations. The Company’s management uses these financial measures for strategic decision making, forecasting future financial results, and evaluating current period financial and operating performance. The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. Furthermore, these measures are not intended to be liquidity measures. Other companies, including other companies in the Company’s industry, may not use these measures or may calculate these measures differently than the Company does, limiting their usefulness as comparative measures. The Company intends to calculate these non-GAAP financial measures in a consistent manner from period to period. A reconciliation of each of the non-GAAP financial measures to the most directly comparable GAAP measures has been provided under the heading “Non-GAAP Reconciliations” in the financial statement tables attached to this press release.

Adjusted Net Income (Loss) Definition:

(1) “Adjusted Net Income (Loss)” is a non-GAAP measure defined by the Company as net income (loss) under GAAP, excluding (to the extent relevant in a particular reporting period): (i) restructuring and other transition costs; (ii) contract termination, product withdrawal and business acquisition expenses; (iii) legal settlement costs; (iv) business development expenses, including licensing costs related to research and development activities; (v) inventory step-up amortization; (vi) interest expense; (vii) foreign currency loss (gain); (viii) fair value adjustment to Nellix® contingent consideration liability; (ix) fair value adjustment of derivative liabilities; and (x) loss on debt extinguishment.

In the three months ended March 31, 2020 and 2019, this GAAP adjustment to net loss specifically represents: (i) restructuring and other transition costs; (ii) contract termination, product withdrawal and business acquisition expenses; (iii) interest expense; (iv) foreign currency loss (gain); (v) fair value adjustment to Nellix® contingent consideration liability; (vi) fair value adjustment of derivative liabilities; and (vii) loss on debt extinguishment.

Adjusted EBITDA Definition:

(2) “Adjusted EBITDA” is a non-GAAP measure defined by the Company as “Adjusted Net Income (Loss)” excluding income tax (benefit) expense, depreciation and amortization expense, and stock-based compensation expense.

ENDOLOGIX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Unaudited

(In thousands, except per share amounts)

 

Quarter Ended

 

 

March 31,

 

 

2020

 

2019

 

Revenue

 

 

 

 

U.S.

$

18,629

 

 

$

22,786

 

 

International

9,881

 

 

12,820

 

 

Total Revenue

28,510

 

 

35,606

 

 

Cost of goods sold

13,378

 

 

12,407

 

 

Gross profit

15,132

 

 

23,199

 

 

Gross margin

 

 

 

 

Operating expenses:

 

 

 

 

Research and development

3,536

 

 

4,787

 

 

Clinical and regulatory affairs

3,165

 

 

3,785

 

 

Marketing and sales

14,496

 

 

16,786

 

 

General and administrative

10,119

 

 

9,416

 

 

Restructuring costs

—

 

 

419

 

 

Total operating expenses

31,316

 

 

35,193

 

 

Loss from operations

(16,184

)

 

(11,994

)

 

Other expense, net

(11,649

)

 

(8,172

)

 

Change in fair value of contingent consideration related to acquisition

300

 

 

200

 

 

Loss on debt extinguishment

(730

)

 

—

 

 

Change in fair value of derivative liabilities

10,175

 

 

(2,023

)

 

Total other expense, net

(1,904

)

 

(9,995

)

 

Net loss before income taxes

(18,088

)

 

(21,989

)

 

Income tax expense

(28

)

 

(39

)

 

Net loss

$

(18,116

)

 

$

(22,028

)

 

 

 

 

 

 

Comprehensive loss, net of taxes:

 

 

 

 

Net loss

$

(18,116

)

 

$

(22,028

)

 

Other comprehensive income (loss) foreign currency translation

748

 

 

(598

)

 

Comprehensive loss

$

(17,368

)

 

$

(22,626

)

 

 

 

 

 

 

Basic and diluted net loss per share

$

(0.90

)

 

$

(2.12

)

 

Shares used in computing basic and diluted net loss per share

20,067

 

 

10,374

 

Non-GAAP Reconciliations:

 

 

 

 

 

 

 

 

 

 

Quarter Ended

 

 

March 31,

 

 

2020

 

2019

 

Net Loss to Adjusted Net Loss:

 

 

 

 

Net loss

$

(18,116

)

 

$

(22,028

)

 

Fair value adjustment to Nellix contingent consideration liability

(300

)

 

(200

)

 

Interest expense

10,527

 

 

8,490

 

 

Foreign currency (gain) loss

1,141

 

 

(400

)

 

Restructuring and other transition costs

—

 

 

419

 

 

Fair value adjustment of derivative liabilities

(10,175

)

 

2,023

 

 

Loss on extinguishment of debt

730

 

 

—

 

 

(1) Adjusted Net Loss

$

(16,193

)

 

$

(11,696

)

 

 

 

 

 

 

Adjusted Net Loss to Adjusted EBITDA:

 

 

 

 

Adjusted Net Loss

$

(16,193

)

 

$

(11,696

)

 

Income tax expense

28

 

 

39

 

 

Depreciation and amortization expense

1,192

 

 

1,735

 

 

Stock-based compensation expense

1,733

 

 

2,362

 

 

(2) Adjusted EBITDA

$

(13,240

)

 

$

(7,560

)

 

ENDOLOGIX, INC.

CONSOLIDATED BALANCE SHEETS

Unaudited

(In thousands, except share and per share amounts)

 

March 31, 2020

 

December 31, 2019

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

40,854

 

 

$

41,560

 

Restricted cash

1,381

 

 

1,200

 

Accounts receivable, net of allowance for doubtful accounts of $1,596 and $1,317, respectively

18,951

 

 

22,392

 

Other receivables

298

 

 

282

 

Inventories

24,486

 

 

26,405

 

Prepaid expenses and other current assets

2,548

 

 

1,864

 

Total current assets

88,518

 

 

93,703

 

Property and equipment, net

12,473

 

 

13,152

 

Goodwill

120,783

 

 

120,814

 

Other intangible assets, net

72,086

 

 

72,603

 

Deposits and other assets

786

 

 

1,124

 

Operating lease right-of-use assets

5,707

 

 

5,768

 

Total assets

$

300,353

 

 

$

307,164

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

12,464

 

 

$

14,024

 

Accrued payroll

21,870

 

 

18,232

 

Accrued expenses and other current liabilities

16,443

 

 

12,931

 

Current portion of debt

167,861

 

 

10,606

 

Revolving line of credit

10,519

 

 

—

 

Total current liabilities

229,157

 

 

55,793

 

Deferred income taxes

150

 

 

150

 

Operating lease liabilities

11,376

 

 

11,621

 

Derivative liabilities

—

 

 

940

 

Other liabilities

1,866

 

 

2,244

 

Contingently issuable common stock

200

 

 

500

 

Debt

4,281

 

 

172,060

 

Total liabilities

247,030

 

 

243,308

 

Commitments and contingencies

 

 

 

Stockholders’ equity:

 

 

 

Series DF-1 convertible preferred stock, $0.001 par value, 1,150,000 shares authorized, 14,649 shares issued and outstanding

—

 

 

—

 

Common stock, $0.001 par value, 170,000,000 shares authorized, 19,215,059 and 18,190,054 shares issued, respectively, and 19,097,506 and 18,098,464 shares outstanding, respectively

19

 

 

18

 

Treasury stock, at cost, 117,553 and 91,590 shares, respectively

(4,271

)

 

(4,235

)

Additional paid-in capital

737,599

 

 

730,729

 

Accumulated deficit

(682,588

)

 

(664,472

)

Accumulated other comprehensive income

2,564

 

 

1,816

 

Total stockholders’ equity

53,323

 

 

63,856

 

Total liabilities and stockholders’ equity

$

300,353

 

 

$

307,164

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20200511005818/en/

INVESTOR CONTACT: Endologix, Inc. Vaseem Mahboob, CFO [phone]